Pericardial effusion and cardiac tamponade: clinical manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation  by Ferreira, David Cavalcanti et al.
REV BRAS HEMATOL HEMOTER. 2014;36(2):159-161
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
www.rbhh.org
A B S T R A C T
 
The authors report a case with pericardial effusion and cardiac tamponade as a rare 
clinical manifestation of chronic graft-versus-host disease in a young man with acute 
myelogenous leukemia submitted to an allogeneic hematopoietic stem cell transplantation 
from a related donor.
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Graft-versus-host disease (GVHD) is a syndrome with variable 
clinical manifestations associated with the time of clinical 
evolution, affected organ and severity of lesions. It arises as a 
result of immunocompetent cells attacking different tissues of 
the recipient.1 Acute GVHD begins at approximately the 19th 
day after transplantation, chronic GVHD usually develops after 
Day (D)+100; however, the same clinical criteria are employed for 
diagnosis, as chronic GVHD can occur even before D+100. The 
acute form of GVHD affects three organs: skin, liver and intestine; 
while the chronic form of GVHD is clinically characterized by 
cutaneous, mucosae, hepatic, gastrointestinal, serous tissue, 
pulmonary and ocular lesions. The most common factors that 
increase the risk of GVHD are donor/recipient human leukocyte 
antigen (HLA) mismatch,  patient and donor age, donor/recipient 
opposite gender and number of T lymphocytes in the inoculum.2 
Despite scientific advances in the area of hematopoietic stem cell 
transplantation (HSCT), including prophylaxis against infection, 
immunosuppressive medications and better intensive clinical 
support techniques for DNA typing, this complication still 
remains the most common cause of morbidity and mortality in 
patients undergoing allogeneic HSCT.3 GVHD with pericardial 
effusion and cardiac tamponade is a rare complication after 
HSCT and its impact is not well defined yet.4 The authors report 
on a case of this complication in a young man with acute 
myelogenous leukemia (AML) submitted to allogeneic HSCT 
from a female donor.
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Case report
A 39-year-old man was admitted to Hospital Santa Marcelina 
(HSM) on July 28, 2007 and was diagnosed with AML [French-
American-British (FAB M2)], confirmed by myelogram (20% 
of myeloid blasts) and immunophenotyping (34% positive 
for CD45 low; CD4, CD13, CD33, CD11 and CD117 positive; 
immature: CD34, CD38, and aberrant expression of CD7). 
Induction therapy was initiated with the D3A7 regimen: 
Daunorubicin (60 mg/m2/day for three days) and Cytarabine 
(200 mg/m2 for seven days). The patient achieved complete 
remission, and consolidation therapy was subsequently 
prescribed. After chemotherapy, the patient was submitted to 
allogeneic HSCT on December 26, 2007 from a female HLA-
identical related donor, but with major ABO blood group 
incompatibility (patient A Rh+ and donor B Rh+). Stem cells 
were collected by apheresis and the total CD34 count was 
5.35  × 106/kg. The patient received prophylactic treatment 
against GVHD with cyclosporin and methotrexate. Grafting 
was observed on D+17 after stem cell infusion. The patient 
evolved during transplantation without any complications 
except for febrile neutropenia which was treated with 
cefepime. He was discharged to an outpatient follow-up and 
received methotrexate, arabinoside-C and dexamethasone 
(MADIT) every two weeks for six cycles and cyclosporine (10 
mg/kg/day). On March 26, 2008, a bone marrow biopsy showed 
30% cellularity with the three series well represented and 
absence of malignant cells. Yet, bone marrow karyotyping 
(20 metaphases) showed cells being 46 XX. The patient was 
progressively weaned off cyclosporine (10/10 days) however 
on D+142 after HSCT he developed chronic GVHD with skin 
lesions similar to scleroderma, mucositis and hepatitis. At 
that time the medical team decided to increase the dose of 
cyclosporine and start prednisone therapy (1 mg/kg/day). By 
D+173, the lesions of the skin and mucous membranes had 
improved; at which time prednisone weaning was begun. On 
April 3, 2009, he was readmitted to the hospital with dyspnea, 
orthopnea, paroxysmal nocturnal dyspnea and generalized 
edema (cardiac tamponade) and was submitted to an urgent 
pericardiocentesis to drain about 1600 mL of sero-bloody fluid. 
An analysis of the liquid showed the following characteristics: 
hemorrhagic aspect, ph = 7.8; glucose = 135 mg/dL; protein 
= 4.6 g/dL albumin = 3.4 g/dL; amylase = 20 U/dL; lactate 
dehydrogenase (dehydrogenase accumulation threshold) = 
335 U/dL; adenosine deaminase (ADA) = 17.3 U/dL; acid-fast 
bacilli (AFB) and fungal cultures were negative. At that time, it 
was decided to treat the patient with empirical treatment for 
tuberculosis and restart prednisone (1 mg/kg/day). The patient 
evolved clinically well and after two weeks of treatment was 
discharged from the hospital in good condition. In June, 2009, 
he was again admitted with signs and symptoms of cardiac 
tamponade. Because of his history, an echocardiography 
was immediately performed which showed pericardial 
effusion with signs of cardiac tamponade. Because of the 
recurrence without a well-defined diagnosis his case was 
discussed with the heart surgeon, who decided to proceed 
with a pericardiostomy and biopsy; a drain was placed in 
the pericardium and 1500  mL of serohematic fluid was 
removed. The biopsy of the pericardium concluded: presence 
of fibrinous exudate with chronic pericarditis and diffuse 
inflammatory lymphoplasmacytic infiltration, more intense 
around the vaso-histological structure compatible with 
GVHD. The immunohistochemical study of the pericardium 
indicated CD20+ (pan B), L26/CD45 Ro (pan T), (UCHL1)/CD138 
plasma cells, CD4 negative, concluding that the pericardium 
was affected by an inflammatory process rich in B and T cells, 
as well as plasma cells. A computed tomography (CT) of the 
thorax on June 26, 2010 showed thickening of the pericardium 
with minimal pericardial effusion, and significant bilateral 
pleural effusion. The drain was kept in the pericardium until 
no more cardiac debit  was observed and the patient remained 
on prednisone (1 mg/kg/day) to control the pericardial GVHD. 
The patient evolved with significant clinical improvement 
and was discharged to outpatient follow-up. 
Discussion
HSCT is an effective therapy for AML. Although used 
in patients with on-going disease, the best results are 
documented in patients undergoing the procedure while in 
first remission.5 In the current case, HSCT was performed 
after chemotherapy and the patient achieved complete 
remission. Pathological and clinical features of chronic 
GVHD are similar to some collagen diseases, in which there 
is a deregulation of the immune system with eosinophilia, 
presence of autoantibodies, hypergammaglobulinemia and 
plasmacytosis. There is frequent involvement of the skin, liver, 
eyes, lungs and gastrointestinal tract. However involvement 
of other tissues, such as serosal tissues, has rarely been 
reported. Sullivan et al. reported serosal tissue involvement 
in 2% of patients with chronic GVHD after HSCT.6 It is known 
that GVHD presents similar clinical manifestations to 
autoimmune diseases, such as systemic sclerosis, systemic 
lupus erythematosus, lichen planus, Sjögren’s syndrome, 
rheumatoid arthritis and primary biliary cirrhosis. It is 
surprising that the incidence of polyserositis is so low.6 The 
patient developed pericardial effusion and cardiac tamponade 
sixteen months after HSCT, in addition to bilateral pleural 
effusion. Pleural tuberculosis is a frequent cause of pleural 
effusion in Brazil. The risk of tuberculosis appears to be 
increased in patients with chronic rheumatic diseases such as 
systemic lupus erythematosus, and in patients on prolonged 
corticosteroid or immunosuppressant therapies.7 In view of 
epidemiological data showing that tuberculosis is a major 
cause of serositis in Brazil and since the patient’s immune 
system was highly suppressed and the adenosine deaminase 
concentration in the pericardial fluid was very close to the 
normal upper limit (17.3 U/dL), we chose to start empirical 
treatment for tuberculosis until the results of the biopsy 
and immunohistochemistry confirmed pericardial GVHD. 
From then on, the patient remained on specific treatment 
for GVHD with cyclosporine and prednisone. There are few 
reports of pleural effusion and pericardial fluid in chronic 
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GVHD. Seber et al. described polyserositis in seven patients 
with recurrent serous effusions after HSCT.8 There are some 
important differences between these cases and the present 
one. In the previously referenced study, four of the HSCT used 
unrelated donors and in six cases serosal effusions occurred 
before D+100 after HSCT; considered as the period for acute 
GVHD. Only three of the seven patients had pericardial 
effusions. The authors of this article highlight the extension 
of pericardial effusion (April: 1600 mL and June: 1500 mL of 
serohematic fluid), the association with pleural effusion, the 
recurrence of serositis, the time of clinical manifestation (16 
months after transplantation) and the severity of it leading to 
cardiac tamponade with imminent risk to life for the patient. 
The pericardium contains, on average, about 50 mL of fluid. 
When there is an accumulation of fluid in the pericardial 
space capable of producing pressure above intracardiac levels, 
cardiac tamponade occurs. This is characterized by increasing 
intracavity pressures with limitation of ventricular filling and 
consequent reduction of cardiac debit leading to hemodynamic 
instability.7 Although pericardial effusion is a rare clinical 
manifestation of GVHD with few cases described in the 
literature, it should not be underestimated by hematologists 
accompanying patients submitted to allogeneic HSCT.
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